AtriCure Q2 2026 Earnings Report

AtriCure EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.03
• Beat/Miss: N/A
• One Year Ago EPS: N/A

AtriCure Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $151.83 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

AtriCure Announcement Details

• Quarter: Q2 2026
• Date: 7/23/2026
• Time: After Market Closes
• Conference Call Date: Thursday, July 23, 2026
• Conference Call Time: 4:30PM ET

AtriCure (NASDAQ:ATRC) is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques. In addition, AtriCure markets the LARIAT Suture Delivery Device for left atrial appendage closure to help reduce stroke risk in AF patients who are unable to tolerate long-term anticoagulation therapy. AtriCure continues to invest in R&D initiatives aimed at expanding its surgical and hybrid EP solutions, as well as digital platforms for intraoperative mapping and post-procedural monitoring.

AtriCure operates internationally with sales and distribution channels across North America, Europe, Asia and select emerging markets. The company collaborates with leading cardiac centers, physician innovators and academic institutions to conduct clinical studies and training programs that support adoption of its technologies. Under the leadership of President and Chief Executive Officer Jonathan M. Cathcart, AtriCure has pursued strategic partnerships and targeted acquisitions to enhance its electrophysiology portfolio and drive long-term growth. The company remains committed to expanding access to safe, effective AF treatments and advancing the standard of care in cardiac surgery and electrophysiology.